ID4 and prostate cancer: Our results are therefore consistent with the epigenetic silencing of Id4 due to promoter hypermethylation in cancers: T-/natural killer acute lymphoblastic leukemia [21], gastric [26], breast [23] colorectal [24], and prostate cancer [37].